New Sustainable Lyophilization Technology Uses Supercritical CO2

Pittsburgh, PA, January 29, 2024 — Thar Process, a US-based CRO and manufacturer of advanced tools for sustainable purification and extraction, today announced it has completed its first pilot scale supercritical CO2 lyophilization system to meet the needs of discovery and GMP drug development labs. The new SuperDry 9000 can spray/freez dry a wide range of compounds, including synthetic pharmaceuticals, biomolecules, fine chemicals, plus natural and inorganic materials.

The new system uses CO2 as an anti-solvent (formerly known as SAS or SEDS), is designed for ease of use and scalability including a new Siemens PLC enabling even more robust CFR 21 Part 11 software, making it ideal for both R&D and clinical scale manufacturing applications. Previous designs of SAS technology tools did not have the power to remove water from biologicals effectively. Additionally, the new system features a number of innovative features, including:

– Compatibility / scalability with smaller, upcoming Thar SuperDry 500 SAS system
– Simplified software that is both easy to use but customizable for experts
– Modular design that allows for easy expansion and customization

Thar Process has already shipped similar systems to customers all over the world, including the United States, Canada, Europe, and Asia. Customers are using the Isolator 3-5 to purify a wide range of synthetic and natural compounds including polymers, biofuels, amino acids, peptides, oligonuclotides, antibody drug conjugates, and proteins.

“We are excited to introduce the SuperDry 9000 and finally step into the large molecule biopharmaceutical market,” said Todd Palcic, CEO of Thar Process. “We use SAS technology in our own GMP toll processing facility for natural products de-oiling, but we are launching the new line of systems to meet the needs of Big Pharma R&D while not neglecting the vast amount of work done by CDMOs, government / university labs and NGOs.

You May Also Like

More From Author

+ There are no comments

Add yours